Question 277 of 433
Do bone drugs, anti-inflammatory drugs, or aspirin extend life?
The short answer
There are intriguing signals for the first two and a clear no for the third.
Zoledronate, a once-yearly infusion for osteoporosis, was associated with 28 percent lower mortality in patients treated after a hip fracture. The reason is not understood. It is not a reason to take it without osteoporosis.
Low-dose colchicine reduced heart events by about 30 percent in people with stable coronary disease and is approved for that. A later trial in people just after a heart attack found no benefit. It is for selected heart patients, not for general use.
Aspirin in healthy older adults caused about as much serious bleeding as the heart trouble it prevented, and did not extend life.
“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer
HUMAN TRIALS — Post-fracture zoledronate and selected coronary colchicine outcomes; routine primary-prevention aspirin lacks net benefit for many.Evidence grade (draft mapping)Grade pendingPart 19, Q277 · Part sources
From Longevity Unmasked by Afshine Ash Emrani, MD, FACC. Medical disclaimer. This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship. Nothing here is meant to diagnose, treat, cure, or prevent any disease. Medicine is personal: a test, drug, supplement, or exercise plan that helps one person can harm another. Do not start, stop, or change any medication or treatment because of something you read in these pages. Talk with a licensed clinician who knows your history first. If you think you are having a medical emergency, call 911. The author disclaims responsibility for any loss or harm arising from use of the information in this book.